Diabetes Care · 2020 · 82 citations · 40 references
Life SciencesEndocrinologyImmunologyAutoimmunityDiabetologyEpidemiologyAutoantibody-mediated DiseaseAutoantigensAutoimmune DiseasesDiabetes MellitusDiabetes PreventionAutoantibody GenerationAutoantibody PathogenesisDiabetes Mellitus PathophysiologyDiabetes-related ComplicationsHierarchical StructuresIslet AutoimmunityType 1 Diabetes Pathophysiology
OBJECTIVE The first-appearing β-cell autoantibody has been shown to influence risk of type 1 diabetes (T1D). Here, we assessed the risk of autoantibody spreading to the second-appearing autoantibody and further progression to clinical disease in The Environmental Determinants of Diabetes in the Young (TEDDY) study. RESEARCH DESIGN AND METHODS Eligible children with increased HLA-DR-DQ genetic risk for T1D were followed quarterly from age 3 months up to 15 years for development of a single first-appearing autoantibody (GAD antibody [GADA], insulin autoantibody [IAA], or insulinoma antigen-2 autoantibody [IA-2A]) and subsequent development of a single second-appearing autoantibody and progression to T1D. Autoantibody positivity was defined as positivity for a specific autoantibody at two consecutive visits confirmed in two laboratories. Zinc transporter 8 autoantibody (ZnT8A) was measured in children who developed another autoantibody. RESULTS There were 608 children who developed a single first-appearing autoantibody (IAA, n = 282, or GADA, n = 326) with a median follow-up of 12.5 years from birth. The risk of a second-appearing autoantibody was independent of GADA versus IAA as a first-appearing autoantibody (adjusted hazard ratio [HR] 1.12; 95% CI 0.88–1.42; P = 0.36). Second-appearing GADA, IAA, IA-2A, or ZnT8A conferred an increased risk of T1D compared with children who remained positive for a single autoantibody, e.g., IAA or GADA second (adjusted HR 6.44; 95% CI 3.78–10.98), IA-2A second (adjusted HR 16.33; 95% CI 9.10–29.29; P < 0.0001), or ZnT8A second (adjusted HR 5.35; 95% CI 2.61–10.95; P < 0.0001). In children who developed a distinct second autoantibody, IA-2A (adjusted HR 3.08; 95% CI 2.04–4.65; P < 0.0001) conferred a greater risk of progression to T1D as compared with GADA or IAA. Additionally, both a younger initial age at seroconversion and shorter time to the development of the second-appearing autoantibody increased the risk for T1D. CONCLUSIONS The hierarchical order of distinct autoantibody spreading was independent of the first-appearing autoantibody type and was age-dependent and augmented the risk of progression to T1D.
40
Diagnosis and Classification of Diabetes Mellitus
Diabetes Care · 2010 · 14K citations · Full text
Diagnosis and Classification of Diabetes Mellitus
Diabetes Care · 2013 · 6K citations · Full text
Seroconversion to Multiple Islet Autoantibodies and Risk of Progression to Diabetes in Children
Anette G. Ziegler, Marian Rewers, Olli Simell et al. · JAMA · 2013 · 1.3K citations · Full text
Medicine, Endocrinology, Pediatrics +13
Anette‐Gabriele Ziegler, Michael Hummel, M Schenker et al. · Diabetes · 1999 · 639 citations